Common breast cancer subtype may benefit from personalized treatment approach

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by scientists at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

Invasive lobular carcinoma, characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers which indicate drug therapies may provide benefits beyond those typically prescribed for the more common . The results recently were published in Cancer Research and will be expanded upon on Tuesday at the American Association for Cancer Research (AACR) Annual Meeting 2014.

Patients with invasive lobular carcinoma typically are treated through surgical removal of the , followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive .

"However, recent analyses suggest that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma," said lead author Matthew Sikora, Ph.D., postdoctoral associate at UPCI, and recipient of this year's AACR-Susan G. Komen Scholar-in-Training Award for this research. "Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to potential targets for drug therapy in future clinical trials, which we are developing."

Early studies in developing these potential targets are the topic of Dr. Sikora's AACR presentation, with a focus on a unique signaling pathway regulated by estrogen specifically in lobular cells.

Related Stories

Breast cancer type linked to paternal cancer

date Nov 28, 2011

The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT). New research published in BioMed Central's ...

Recommended for you

Researchers confirm gene p73's role in tumor growth

date 7 hours ago

A team of researchers at National Cancer Centre Singapore (NCCS) and Singapore General Hospital (SGH) has determined dual functionality gene p73, in both the promotion and suppression in tumour growth. The NCCS team also ...

Researchers define unique group of high-risk lymphoma patients

date 10 hours ago

The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.